Kanak Raina

VP @ Quarry Thera. Ex-Head of Biology @ Halda Tx; Ex-Arvinas. Drug Discovery. Induced Proximity Therapeutics. Opinions my own.

[Banana Oncology @Banana_Oncology]

More ctDNA-bases interventional study. Seems like ctDNA/MRD is hitting the stage on all kinds of indications this year!

[Kanak Raina @rainakanak]

Two hours very well spent. great story, well told https://t.co/IqJQfNGmzF

[Samuel Hume @DrSamuelBHume]

Trial by trial, step by step

How precision medicine improved outcomes in ALK-positive lung cancer (which typically affects younger, non-smokers):

[Kanak Raina @rainakanak]

One for all proxi-drug enthusiasts

[William Gibson @wgibson]

What if a small molecule could activate a transcription factor program in one cell type and destroy the same pathway in another? In our new preprint, we describe one such story on bifunctional molecules that toggle between transactivation and repression.

[Samuel Hume @DrSamuelBHume]

How outcomes in relapsed/refractory multiple myeloma changed, from 1986 to 2026

[Ash Jogalekar @curiouswavefn]

Great thread. Most seminal scientific theories and ideas came from small data + serendipity, not Big Data. Correlations can be very useful, but massive correlations don’t by themselves a theory make.

[Peter Tulip @peter_tulip]

"In medical research, there’s a practice of ending a study early when the results are too striking to ignore. ... When an intervention works this clearly, you change what you do."

[Banana Oncology @Banana_Oncology]

While not publicly traded, Halda presented one of the most exciting data during the AACR triple meeting, ultra novel RIPTAC modality

Steep and durable responses with this new modality! Cheers!

https://t.co/5wd8svxmpc

[Andy Hahn @OncHahn]

(5/6) Most exciting part is this novel MOA has very encouraging prelim activity against mCRPC. In pts with ≥ 6 wks tx, PSA50 was 59%, PSA90 was 32%, PR in 5/5 pts with RECIST-evaluable, and activity regardless prior tx or genomic alterations

[Andy Hahn @OncHahn]

(1/6) Introducing an AR RIPTAC therapy, HLD-0915, for men with mCRPC by @HaldaTx We presented data from the FIH, phase 1 trial at the @AACR #Targets25 meeting. Here’s the Tweetorial for this active, tolerable, oral med and link to the slides https://t.co/mKbro4l0Or

[Sally Church @MaverickNY]

Remember all those BET/bromodomain inhibitors/degraders that went by the wayside due to severe toxicities and a poor TI?
It turns out there's a cool and better way to drug the key BRD4 target if you choose wisely...
https://t.co/gBdDD4JINV

[Zach Klaassen @zklaassen_md]

Drug Approvals in 🇺🇸 for Prostate Cancer (2010-2025)

Go ahead and bookmark this beauty from @PBarataMD

@urotoday #ESMO25

[Massimo @Rainmaker1973]

In Himachal Pradesh in the northern part of India, a nurse named Kamla Devi bravely crosses a raging river to tend to and vaccinate a newborn.
https://t.co/AGhrrEx5I0

[Simon Barnett @SimonDBarnett]

Ever since the Lady Gaga migraine ads, I've wondered what the ODT meant in Nurtec ODT.

It means Orally Disintegrating Tablet.

Okay, so what? Lots of drugs are oral. Why does Nurtec have ODT in the brand name while most drugs don't?

I ended up in a drug branding rabbit hole.

[Yüksel Ürün @DrYukselUrun]

Tumor-agnostic approvals by @US_FDA
@OncJournal @Nakul2234 @MDAndersonNews
#precision #agnostic @OncoAlert @OncBrothers
https://t.co/fY3sjvHyVx

[Biotech2k @Biotech2k1]

Statistics show that 70% of patients prefer a once daily pill over any other type of route of administration.

[Kanak Raina @rainakanak]

Pretty much how i feel about Adobe Reader.

[Kanak Raina @rainakanak]

whut

[Stephen V Liu, MD @StephenVLiu]

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

[Kanak Raina @rainakanak]

Nice work building on the RIPTAC concept. Congrats to all authors https://t.co/ojZgGXHTu3

[Uromigos @Uromigos]

2/N
Take Home Points in Metastatic Hormone Sensitive Prostate Cancer (mHSPC):

· ADT + ARPI is the clear minimum standard across disease volume and synchronous/metachronous

· Docetaxel addition is generally not favored in low-volume disease, should be avoided in low-volume, metachronous disease and generally favored in high-volume disease

· ADT monotherapy should be avoided

· XRT to the primary is highly favored in synchronous low-volume disease and has only a limited role in synchronous high-volume disease.